Ph3 Study of PF-07248144 + Fulvestrant in HR+ HER2 Breast Cancer
Phase III Clinical Trial
C4551002: AN INTERVENTIONAL OPEN-LABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF-07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATOR�S CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK4/6 INHIBITOR-BASED THERAPY
Participating Locations